A San Diego contract manufacturer that specializes in biologics production, a California academic-business consortium, and the government of Taizhou, China are getting together to build a 200,000 square foot CMO facility in China that will focus on cost-effective small-batch manufacturing of biologic products. The new venture will be called Pacific Biopharma. San Diego’s PacificGMP, a three-year-old contract manufacturing enterprise, will contribute its experience with small-batch biologics manufacturing. QB3, a consortium of three University of California Universities and business leaders, will throw in its contacts and desire to produce prospective biologic drugs in small quantities. And the Taizhou government will invest an unspecified amount of money to build the new facility. More details...